LitAlert ~~ GeneLit.com

    • Editorial: Prostate Cancer Genomics: Application at Different Stages of a Patient's Journey.
    • Poon DM, Azad A, Castro E, Kanesvaran R, Sartor O.
    • Front Oncol. 2022 Nov 21;12:1101678. doi: 10.3389/fonc.2022.1101678.

    • UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.
    • Hanson H, Kulkarni A, Loong L, Kavanaugh G, Torr B, Allen S, Ahmed M, Antoniou AC, Cleaver R, Dabir T, Evans DG, Golightly E, Jewell R, Kohut K, Manchanda RM, Murray A, Murray J, Ong KR, Rosenthal AN, Woodward ER, Eccles DM, Turnbull C, Marc Tischkowitz M, On behalf of Consensus meeting attendees, Lalloo F.
    • J Med Genet. 2022 Nov 21:jmg-2022-108898. doi: 10.1136/jmg-2022-108898. Epub ahead of print.

    • In silico and structure-based assessment to classify VUS identified in the a-helical domain of BRCA2.
    • Khan MA, Varma AK.
    • J Biomol Struct Dyn. 2022 Nov 20:1-11. doi: 10.1080/07391102.2022.2148127. Epub ahead of print.

    • Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
    • Yanaihara N, Yoshino Y, Noguchi D, Tabata J, Takenaka M, Iida Y, Saito M, Yanagida S, Iwamoto M, Kiyokawa T, Chiba N, Okamoto A.
    • Gynecol Oncol. 2022 Nov 17;168:83-91. doi: 10.1016/j.ygyno.2022.11.006. Epub ahead of print.

    • Dose Adjustment of Poly (ADP-Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment.
    • Zhao D, Long X, Wang J.
    • Drug Des Devel Ther. 2022 Nov 14;16:3947-3955. doi: 10.2147/DDDT.S387920.